FOCUS 1: A randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue SUPPL.3, 2011, Pages

  File, Thomas M ^a,b   Low, Donald E ^c   Eckburg, Paul B ^d,e   Talbot, George H ^f   Friedland, H David ^d,e   Lee, Jon ^d,e   Llorens, Lily ^d,e   Critchley, Ian A ^d,e   Thye, Dirk A ^d,e   Pullman, J ^g   Giordano, P ^g   Welker, J ^g   Manos, P ^g   Mehra, P ^g   De Santo, J ^g   Venkateswaralu, B ^g   Gerald Schrock, C ^g   Tillis, W ^g   Winetz, J A ^g   Gonzalez, J M ^g   Ramage, A ^g   Eisenhower, D D ^g   Koegelenberg, C ^g   Engelbrecht, I ^g   Jurgens, J ^g   Mitha, I ^g   Breedt, J ^g   Gani, M ^g   Roos, J ^g   Basson, M ^g   Van Zyl, L ^g   Meeding, R ^g   Fulat, M ^g   Le Roux, M ^g   Bonvehi, P E ^g   Ganaha, M C ^g   Gurini, A L ^g   Daniel Lopardo, G ^g   Cristina, L ^g   Edwardo Prieto, S ^g   Rodiguez, C G ^g   Augusto Teijeiro, R ^g   Carmen Pallone, E ^g   Pryluka, D H ^g   da Cunha, C A ^g   da Silva, N B ^g   de Faria Freire, A T ^g   Ferreira Starling, C E ^g   Costa Fiterman, J ^g   Gongora Rubio F ^g   Carlos Losso, L ^g   Patelli, M ^g   Souza Lima, J ^g   Zimermann Teixeira, P J ^g   Carmo Moreira, M A ^g   Abreu de Oliveira, J C ^g   Roudas, V ^g   Gamal, E A ^g   Leschenko, I ^g   Rudnov, V A ^g   Yevdokimova, A G ^g   Vertkin, A L ^g   Ambalov, Y M ^g   Dvoryashina, I V ^g   Zilber, E ^g   Khamitov, R F ^g   Galustyan, A N ^g   Reshetko, O V ^g   Senior, V A ^g   Grosan, M F ^g   Jimborean, G ^g   Lupse, M ^g   Aron, G ^g   Olteanu, D ^g   Puschita, M ^g   Gavris, C ^g   Tudorache, V M ^g   Youroukova, V ^g   Petkova, M ^g   Troshanova, E ^g   Dzhabalyan, M ^g   Kavtaradze, G ^g   Makhviladze, M ^g   Tabukashvili, R ^g   Pons, M ^g   Garbino, J ^g   Genne, D ^g   Rothen, M ^g   de Saracho, J O ^g   Capelastegui, A ^g   Menendez, R ^g   Torres, A ^g   Shum, C ^g   Falco, V ^g   Bouza, E ^g   Bru, J P ^g   Misset, B ^g   Megarbane, B ^g   Sollet, J P ^g   Molina, J M ^g   Dalhoff, K ^g   Lorenz, J ^g   Petermann, W ^g   Rohde, G ^g   Schumann, C ^g   Tasci, S ^g   Zerbst, J ^g   Auch Schwelk, W ^g   Suttorp, N ^g   Henrich, R ^g   Fertl, A ^g   Grohe, C ^g   Jakobeit, C ^g   Deppermann, K M ^g   Batura Gabryel, H ^g   Pupek Musialik, D ^g   Piotrowicz, P ^g   Marcisz, C ^g   Czarnobilski, K ^g   Jankowska, R ^g   Janik, K ^g   Gutowska Jablonska, M ^g   Hamankiewicz, M ^g   Kus, J ^g   Rydzewski, A ^g   Dulawa, J ^g   Ziolko, E ^g   Baranska, E ^g   Wendland, M ^g   Trebas Pietras, E ^g   Tyszkiewic, I ^g   Bonelli, J ^g   Baliko Z ^g   Bisits, M ^g   Losonczy, G ^g   Mark, Z ^g   Albert, I ^g   Francovszky, E ^g   Fonay, K ^g   Pertseva, T ^g   Yefimov, V ^g   Havrysyuk, V ^g   Melnyk, V ^g   Yashyna, L ^g   Monogarova, N ^g   Kolchyn, Y ^g   Dutka, R ^g   Smolyanyi, O ^g   Tryshchuk, N ^g   Kaydashev, I ^g   Rodionova, V ^g   Neyko, V ^g   Chopey, I ^g   Alekniene, B ^g   Kramilius, G ^g   Naudziunas, S ^g   Miliauskas, S ^g   Nausediene, V ^g   Valavicius, A ^g   Mitic Milikic, M ^g   Celeketic, D ^g   Lazic, Z ^g   Milinic, N ^g   Pejcic, T ^g   Sukles, K ^g   Jaanus, M ^g   Meriste, S ^g   Ahmad Mahayiddin, D H ^g   Bin Abdul Muttalif, A P ^g   Kuang Kiat, K ^g   Binte, R ^g   Manap, A ^g   Bt Md Tarekh, N A ^g   Anekthananon, T ^g   Mootsikapun, P ^g   Intalapaporn, P ^g   Pothirat, C ^g   Horsin, P ^g   Churchottaworn, C ^g   Wattanathum, A ^g   Dukat, A ^g   Plutinsky, J ^g   more..

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b SUMMA HEALTH SYSTEM   (United States)

^c MOUNT SINAI HOSPITAL   (Canada)

^d Cerexa Inc   (United States)

^e FOREST RESEARCH INSTITUTE   (United States)

^f Talbot Advisors LLC   (United States)

^g NONE

Author keywords

Antimicrobial therapy; CABP; CAP; Streptococcus pneumoniae

Indexed keywords

CEFTAROLINE FOSAMIL; CEFTRIAXONE; CLARITHROMYCIN;

ADULT; ARTICLE; ASTHMA; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; EMPYEMA; FEMALE; GASTROENTERITIS; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; INSOMNIA; INTENTION TO TREAT ANALYSIS; LUNG INSUFFICIENCY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NONHUMAN; PHASE 3 CLINICAL TRIAL; PHLEBITIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SUDDEN DEATH; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; AGED; CHRONIC OBSTRUCTIVE LUNG DISEASE; CREATINE KINASE BLOOD LEVEL; DRUG FATALITY; LABORATORY TEST; LUNG ABSCESS; LUNG EMBOLISM; PLEURA EFFUSION; PNEUMONIA; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BACTERIA; CEFTRIAXONE; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME;

EID: 79954622500     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr096     Document Type: Article

References (29)

1. File TM. Community-acquired pneumonia. Lancet 2003; 362: 1991-2001.
2. Heron M, Hoyert DL, Murphy SL et al. National Vital Statistics Reports. Deaths: Final Data for 2006. April 17, 2009. http://www.cdc.gov/nchs/data/nvsr/nvsr57/nvsr57_14.pdf (26 July 2010, date last accessed).
3. DeFrances CJ, Lucas CA, Buie VC et al. National Health Statistics Reports. 2006 National Hospital Discharge Survey. July 30, 2008. http://www.cdc.gov/nchs/data/nhsr/nhsr005.pdf (26 July 2010, date last accessed).
4. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med 2009; 360: 1418-28.
5. Lim WS, Baudouin SV, George RC et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 Suppl 3: iii1-55.
6. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2: S27-72.
7. Ge Y, Biek D, Talbot GH et al. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008; 52: 3398-407.
8. Iizawa Y, Nagai J, Ishikawa T et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J Infect Chemother 2004; 10: 146-56.
9. Sader HS, Fritsche TR, Kaniga K et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 2005; 49: 3501-12.
10. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50.
11. File TM Jr, Low DE, Eckburg PB et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51: 1395-405.
12. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Clinical Safety Data Management: Definitions and Standards for Expedited Reporting E2A. October 27, 1994. http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html (4 March 2011, date last accessed).
13. Niederman MS, Craven DE, Bonten MS et al. American Thoracic Society and the Infectious Diseases Society of America guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
14. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Seventh Edition: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
15. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Eighteenth Informational Supplement M100-S18. CLSI, Wayne, PA, USA, 2008.
16. Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med 1990; 9: 1447-54.
17. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4: 213-26.
18. Niederman MS, Mandell LA, Anzuetto A et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54.
19. FDA. Guidance for Industry: Community-Acquired Bacterial Pneumonia: Developing Drugs for Treatment. March 2009. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm123686.pdf (26 July 2010, date last accessed).
20. Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other b-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother 2010; 54: 1670-77.
21. Moisan H, Pruneau M, Malouin F. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother 2010; 65: 713-6.
22. Tanaseanu C, Bergallo C, Teglia O et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008; 61: 329-38.
23. Ortiz-Ruiz G, Vetter N, Isaacs R et al. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies. J Antimicrob Chemother 2004; 53 Suppl S2: ii59-66.
24. Pertel PE, Bernardo P, Fogarty C et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 2008; 46: 1142-51.
25. ® (Tigecycline) for Intravenous Use: Prescribing Information. Philadelphia, PA: Wyeth Pharmaceuticals, Inc., July 2010.
26. Corey GR, Wilcox MH, Talbot GH et al. on behalf of the CANVAS 1 investigators. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 Suppl 4: iv41-51.
27. Corey GR, Wilcox M, Talbot GH et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51: 641-50.
28. Wilcox MH, Corey GR, Talbot GH et al. on behalf of the CANVAS 2 investigators. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 Suppl 4: iv53-65.
29. ® (Cefepime Hydrochloride, USP) for Injection: Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Co., March 2009.